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Obesity and prostate cancer-specific mortality after radical
prostatectomy: results from the Shared Equal Access Regional
Cancer Hospital (SEARCH) database
AC Vidal1, LE Howard2, SX Sun2, MR Cooperberg3, CJ Kane4, WJ Aronson5,6, MK Terris7,8, CL Amling9 and SJ Freedland1,2
BACKGROUND: At the population level, obesity is associated with prostate cancer (PC) mortality. However, few studies analyzed
the associations between obesity and long-term PC-specific outcomes after initial treatment.
METHODS: We conducted a retrospective analysis of 4268 radical prostatectomy patients within the Shared Equal Access Regional
Cancer Hospital (SEARCH) database. Cox models accounting for known risk factors were used to examine the associations between
body mass index (BMI) and PC-specific mortality (PCSM; primary outcome). Secondary outcomes included biochemical recurrence
(BCR) and castration-resistant PC (CRPC). BMI was used as a continuous and categorical variable (normal o25 kg/m2, overweight
25–29.9 kg/m2 and obese ⩾ 30 kg/m2). Median follow-up among all men who were alive at last follow-up was 6.8 years
(interquartile range = 3.5–11.0). During this time, 1384 men developed BCR, 117 developed CRPC and 84 died from PC. Hazard ratios
were analyzed using competing-risks regression analysis accounting for non-PC death as a competing risk.
RESULTS: On crude analysis, higher BMI was not associated with risk of PCSM (P= 0.112), BCR (0.259) and CRPC (P= 0.277).
However, when BMI was categorized, overweight (hazard ratio (HR) 1.99, P= 0.034) and obesity (HR 1.97, P= 0.048) were
significantly associated with PCSM. Obesity and overweight were not associated with BCR or CRPC (all P⩾ 0.189). On multivariable
analysis adjusting for both clinical and pathological features, results were little changed in that obesity (HR = 2.05, P= 0.039) and
overweight (HR = 1.88, P= 0.061) were associated with higher risk of PCSM, but not with BCR or CRPC (all P⩾ 0.114) with the
exception that the association for overweight was no longer statistical significant.
CONCLUSIONS: Overweight and obesity were associated with increased risk of PCSM after radical prostatectomy. If validated in
larger studies with longer follow-up, obesity may be established as a potentially modifiable risk factor for PCSM.
Prostate Cancer and Prostatic Diseases (2017) 20, 72–78; doi:10.1038/pcan.2016.47; published online 4 October 2016
INTRODUCTION
At the population level among cancer-free men, obesity is
associated with future risk of prostate cancer (PC) mortality.1–5
Thus, obesity may biologically be associated with aggressive PC.
However, other explanations exist. First, obese men may be less
aggressively screened leading to delayed detection. Second, PC can
be more difficult to detect in obese men including physical
challenges in performing a digital rectal examination6 and lower
PSA7–10 further contributing to delayed detection. Third, obese men
may receive less aggressive and less effective treatment. Four,
obese men are less likely to undergo radical prostatectomy (RP),
which some studies have shown results in lower PC death
rates,11–14 and obese men are more likely to have positive margins
at surgery.15 Recent reports have confirmed that obesity is
associated with high-grade PC at diagnosis.1,16,17 We also previously
showed that obese men undergoing RP had higher-grade and
larger tumors.18 How obesity impacts long-term PC outcomes
among men diagnosed early with localized disease and treatment
aggressively is less clear.
A meta-analysis found a 21% increased risk of biochemical
recurrence (BCR) after RP per 5 kg/m2 increase in body mass index
(BMI) among 16 studies.2 However, only six studies followed men
after treatment for PC-specific mortality (PCSM) and found a trend
(hazard ratio (HR) 1.20 per 5 kg/m2; P= 0.06) for BMI to be
associated with increased PCSM.2 Of these six studies, only one
examined a RP population of 5 313 men and found no significant
association between BMI and PCSM, although this study was
single center and nearly all men were Caucasian.19 Since
publication of that meta-analysis, one other study20 examined
an RP cohort and found that a BMI 30–o35 kg/m2 was associated
with PCSM (HR 1.51, P= 0.040), whereas a BMI ⩾ 35 kg/m2 was not
(HR 1.58, P= 0.356). This study was also a single center of nearly all
Caucasian men.20
Using the Shared Equal Access Regional Cancer Hospital
(SEARCH) database, we previously reported that a BMI ⩾ 35 kg/m2
was associated with a higher BCR risk compared with normal
weight,21 as shown by others.22,23 However, BCR is not
always correlated with PCSM.24,25 Examining longer-term
outcomes is needed, including response to salvage therapy (that
is, androgen-deprivation therapy (ADT)) and ultimately PCSM.
How obesity influences outcomes after salvage ADT is unknown
except for one prior study from our group using SEARCH, which
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only examined men who received early hormonal therapy for BCR
after RP.26
Using the SEARCH database, we examined the effect of obesity
at the time of RP on long-term PC-specific outcomes after RP
including BCR, castrate resistant PC (CRPC) and PCSM (our primary
outcome). We hypothesized obesity is associated with worse
prognosis in all outcome measures.
MATERIALS AND METHODS
Study population
After obtaining institutional review board approval, we combined data
from patients undergoing RP at six Veterans Affairs Medical Centers (West
Los Angeles, San Diego and Palo Alto, CA; Augusta, GA; and Durham and
Asheville, NC) into SEARCH.27 We included men treated in 1990 or later as
few men treated before that had BMI data available. We excluded patients
with missing data on PSA (n=108), biopsy Gleason score (n=399), BMI
(n=362), pathological Gleason score (n= 34), positive surgical margins
(n=38), extracapsular extension (n= 90) and seminal vesicle invasion
(n=19), resulting in a study population of 4268 men.
Statistical analysis
Our primary outcome was PCSM after RP. Death from PC was defined as
death in any patient with metastases showing progression following ADT
without another cause of death based on a thorough chart review.
Secondary outcomes included BCR, CRPC and time to secondary
treatments (radiation (XRT) or ADT). BCR was defined as a single
PSA40.2 ng ml− 1, two concentrations at 0.2 ng ml− 1 or salvage treat-
ment for an elevated post-operative PSA.
As PCSM can result from either aggressive disease or less aggressive
treatment, we also evaluated whether BMI was associated with receipt of
secondary therapies such as adjuvant/salvage radiation therapy and ADT.
Patients who received radiation for an undetectable PSA were
considered as having adjuvant radiation and were censored for BCR at
that time as not having recurred. However, these men were included in
Table 1. Clinical and pathological features of men who underwent radical prostatectomy
Normal weight Overweight Obese P-value
BMIo25 kg/m2 25⩽ BMIo30 kg/m2 BMI⩾ 30 kg/m2
No. patients, n (%) 955 (22) 1941 (45) 1372 (32) –
Age, mean± s.d. 62.5± 6.3 62.1± 6.2 61.2± 6.1 o0.001a
Race, n (%)b 0.119c
White 549 (58) 1190 (62) 794 (58)
Black 373 (39) 675 (35) 529 (39)
Other 29 (3) 60 (3) 37 (3)
Center, n (%) o0.001c
Center A 223 (23) 459 (24) 234 (17)
Center B 104 (11) 238 (12) 158 (11)
Center C 162 (17) 352 (18) 288 (21)
Center D 203 (21) 358 (18) 301 (22)
Center E 145 (15) 307 (16) 233 (17)
Center F 118 (12) 227 (12) 158 (12)
Year of surgery o0.001d
Median (Q1–Q3) 2005 (2000–2010) 2006 (2002–2011) 2007 (2003–2011)
PSA (ng ml− 1) o0.001d
Median (Q1–Q3) 7.1 (5.0–11.1) 6.3 (4.7–9.5) 6.1 (4.7–9.0)
Clinical stage, n (%)b 0.093c
T1 543 (59) 1141 (61) 843 (63)
T2–T4 381 (41) 741 (39) 491 (37)
Biopsy Gleason sum, n (%) 0.003c
2–6 503 (53) 893 (46) 610 (44)
3+4 241 (25) 516 (27) 393 (29)
4+3 97 (10) 260 (13) 170 (12)
8–10 114 (12) 272 (14) 199 (14)
Pathological Gleason sum, n (%) 0.028c
2–6 319 (33) 603 (31) 378 (28)
3+4 366 (38) 715 (37) 561 (41)
4+3 153 (16) 335 (17) 242 (18)
8–10 117 (12) 288 (15) 191 (14)
Positive surgical margins, n (%) 368 (39) 757 (39) 573 (42) 0.186c
Extracapsular extension, n (%) 181 (19) 396 (20) 259 (19) 0.472c
Seminal vesicle invasion, n (%) 93 (10) 209 (11) 138 (10) 0.647c
Positive lymph nodes, n (%) 0.480c
No 616 (65) 1253 (65) 846 (62)
Yes 22 (2) 47 (2) 33 (2)
Not done 317 (33) 641 (33) 493 (36)
Follow-up time (years)e 0.050d
Median (Q1–Q3) 7.0 (3.5–11.2) 7.0 (3.6–11.2) 6.3 (3.3–10.6)
Abbreviation: BMI, body mass index. aP-value calculated using analysis of variance test. bRace was missing on 4 normal weight, 16 overweight and 12 obese
men. Clinical stages were missing on 31 normal weight men, 59 overweight men and 38 obese men. cP-value calculated using χ2 test. dP-value calculated using
Kruskal–Wallis test. eFollow-up time was calculated on men who did not die. The bold numbers indicate that the associations are significant.
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models predicting CRPC and PCSM. CRPC was defined using the PC
Working Group Two criteria: a 25% PSA increase from ADT PSA nadir and a
PSA increase ⩾ 2 ng ml− 1.28 Patients who never received ADT were
included in the models and considered as not reaching the end-point of
CRPC. Our exposure, BMI was abstracted from the medical records at the
time of, but before RP and categorized as normal weight (o25 kg/m2),
overweight (25–29.9 kg/m2) and obese (⩾30 kg/m2). Differences in
demographic and clinicopathological features across BMI categories were
examined using analysis of variance-tests for normally distributed
continuous variables, Kruskal–Wallis tests for non-normally distributed
continuous variables, and χ2 tests for categorical variables.
The associations between BMI and various end points were analyzed
using crude and adjusted competing-risks regression models accounting
for non-PC death as a competing risk.28 Given the modest number of PCSM
and CRPC events raising concerns that fully adjusted models may be
overfit, the crude analyses were considered primary and the adjusted
models secondary analyses. For BCR, there were sufficient events such that
overfitting is not an issue and thus the multivariable models were
considered primary. Time zero for all analyses was the time of RP. BMI was
treated as a continuous and categorical variable. Two adjusted models
were fit. The first model was adjusted for VA center and clinical
characteristics: age at surgery (continuous), PSA (log-transformed and
continuous), biopsy Gleason sum (2–6 vs 7 (3+4) vs 7 (4+3) vs 8–10) and
surgery year (continuous). The second model was additionally adjusted for
pathological characteristics: pathological Gleason sum (2–6 vs 7 (3+4) vs 7
(4+3) vs 8–10), positive margins (no vs yes), extracapsular extension (no vs
yes), seminal vesicles (no vs yes) and lymph node involvement (no/not
done vs yes). Collinearity among variables was tested with the variance
inflation factor and none of the covariates were collinear. Results are
shown graphically using cumulative incidence curves.
SAS 9.3 (SAS Institute, Cary, NC, USA) and Stata 13.1 (Stata, College
Station, TX, USA) were used and statistical significance was two-sided with
Po0.05.
RESULTS
Baseline characteristics by BMI categories
Baseline characteristics of the 4268 men are shown in Table 1.
Overall, 955 (22%) men had normal weight, 1941 (45%) were
overweight and 1372 (32%) were obese. A higher BMI was
associated with younger age at surgery (Po0.001), lower PSA
(median 7.1 vs 6.3 vs 6.1; Po0.001), and a shorter follow-up time
(P=0.050). Biopsy Gleason sum (P=0.003) and pathological
Gleason sum (P=0.028), were different across BMI categories,
men with higher BMI had fewer Gleason 2–6 tumors (53% vs 46%
vs 44%; 33% vs 31% vs 28%, respectively), There was no association
with disease stage (P=0.093), positive margins (P=0.186), extra-
capsular extension (P=0.472), seminal vesicle invasion (P=0.647)
and positive lymph nodes (P=0.480).
Median follow-up among all men who were alive at last follow-
up was 6.8 years (interquartile range = 3.5–11.0). Follow-up data
for 410 years was available on 1309 men. During this time 1384
(32.4%) men developed BCR, 117 (2.7%) developed CRPC and 84
(2.0%) died from PC.
Table 2. Hazard ratios for the associations between BMI and PCSM, BCR, and CRPC
PCSMa BCRa CRPCa
N HR 95% CI P-value N HR 95% CI P-value N HR 95% CI P-value
Unadjusted
BMI 84/4268 1.03 0.99–1.07 0.112 1384/4263 1.01 1.00–1.02 0.259 117/4268 1.02 0.99–1.05 0.277
BMI category
Normal 12/955 1.00 Ref – 316/954 1.00 Ref – 22/955 1.00 Ref –
Overweight 44/1941 1.99 1.06–3.76 0.034 626/1938 0.99 0.86–1.13 0.862 57/1941 1.39 0.85–2.26 0.189
Obese 28/1372 1.97 1.01–3.86 0.048 442/1371 1.03 0.89–1.19 0.721 38/1372 1.42 0.84–2.38 0.190
Model 1b
BMI 84/4268 1.05 1.02–1.10 0.013 1384/4263 1.02 1.01–1.03 0.004 117/4268 1.04 1.00–1.07 0.064
BMI category
Normal 12/955 1.00 Ref – 316/954 1.00 Ref – 22/955 1.00 Ref –
Overweight 44/1941 2.00 1.05–3.81 0.036 626/1938 1.07 0.93–1.23 0.350 57/1941 1.34 0.81–2.24 0.258
Obese 28/1372 2.52 1.25–5.06 0.010 442/1371 1.18 1.01–1.38 0.039 38/1372 1.72 0.99–2.98 0.055
Model 2c
BMI 84/4268 1.03 0.99–1.07 0.121 1384/4263 1.01 1.00–1.02 0.049 117/4268 1.02 0.99–1.06 0.182
BMI category
Normal 12/955 1.00 Ref – 316/954 1.00 Ref – 22/955 1.00 Ref –
Overweight 44/1941 1.88 0.97–3.63 0.061 626/1938 1.05 0.91–1.22 0.484 57/1941 1.36 0.81–2.30 0.244
Obese 28/1372 2.05 1.04–4.06 0.039 442/1371 1.11 0.94–1.30 0.208 38/1372 1.56 0.90–2.70 0.114
Abbreviations: BCR, biochemical recurrence; BMI, body mass index; CI, confidence interval; CRPC, castration-resistant prostate cancer; HR, hazard ratio; PC,
prostate cancer; PCSM, prostate cancer-specific mortality. aAccounting for competing risk of non-PC-specific death. bAdjusted for clinical characteristics: age,
PSA, biopsy Gleason score, surgical center and year of surgery. cAdjusted for clinical and pathological characteristics: age, PSA, year of surgery, surgical center,
pathological Gleason score, positive margins, extracapsular extension, seminal vesicles and lymph node involvement. The bold numbers indicate that the
associations are significant.
Figure 1. Cumulative incidence curve for prostate cancer-specific
mortality (PCSM) by obesity groups.
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Primary outcome: PCSM among BMI categories
On competing risk univariable analysis, both overweight (HR=1.99,
95% confidence interval (CI) 1.06–3.76, P=0.034) and obesity
(HR= 1.97, 95% CI 1.01–3.86, P=0.048) were associated with
increased PCSM risk (Table 2; Figure 1). Results were similar after
adjusting for clinical characteristics (Table 2). Although results were
slightly attenuated after further adjusting for pathological features
with overweight (HR=1.88, 95% CI 0.97–3.63, P=0.061) no longer
being statistically significantly associated with PCSM, the associa-
tion with obesity (HR= 2.05, 95% CI 1.04–4.06, P=0.039) remained
significant (Table 2). When BMI was treated as a continuous
variable, higher BMI was not associated with higher PCSM risk on
both crude and multivariable analyses (all P⩾ 0.112), although
when adjusting for clinical characteristics only a higher BMI was a
predictor of PCSM (HR=1.05, 95% CI 1.02–1.10, P=0.013).
Secondary outcome: BCR among BMI categories
In the unadjusted model and after accounting for competing risks,
BMI either as a continuous or as a categorical variable was not
associated with BCR (all P⩾0.259; Table 2; Figure 2). Obesity was
significantly associated with BCR after adjusting for clinical
characteristics (HR= 1.18, 95% CI 1.01–1.38, P=0.039) but not after
adjusting for clinical and pathological features (HR=1.11, 95% CI
0.94–1.30, P=0.208; Table 2). After multivariable adjustment,
overweight was not associated with BCR risk (Table 2). When BMI
was treated as a continuous variable, it was not associated with BCR
in univariable analysis (P=0.259) but was significantly associated
with BCR after multivariable adjustment for either clinical char-
acteristics (P=0.004) or after adjusting for clinical and pathological
features (P=0.049).
Secondary outcome: secondary treatments among BMI categories
As PCSM can result from either aggressive disease or less
aggressive treatment, we evaluated whether BMI was associated
with receipt of secondary therapies (that is, the aggressiveness of
treatment). During follow-up, 968 men received adjuvant/salvage
radiation therapy and 667 received ADT.
On unadjusted analysis, obese men were equally likely to receive
ADT (P=0.331; Table 3). However, after adjusting for clinical
(P=0.044), but not for clinical and pathological (P=0.132)
characteristics, there was a trend for obese men to be more likely
to receive ADT. Overweight men had equal risks of receiving ADT
(all P⩾ 0.273). When treated as a continuous variable, higher BMI
was associated with greater risk of receiving ADT on multivariable
analysis adjusted for clinical characteristics (P=0.012), although the
association on unadjusted (P=0.112) or models adjusted for both
clinical and pathological characteristics (P=0.077) did not reach
statistical significance.
Although overweight was not associated with receipt of
radiation therapy (all P⩾ 0.316), obese patients were ~ 25% more
likely to receive radiation therapy compared with normal weight
patients (P= 0.012; Table 3). Results were similar after adjusting for
clinical characteristics. Higher BMI, as a continuous variable, was
associated with a higher likelihood of receiving radiation on
unadjusted and adjusted analysis (all P⩽ 0.004).
Secondary outcome: CRPC among BMI categories
On univariable competing risk analysis, overweight and obesity
were not associated with CRPC (HR 1.39, 95% CI 0.85–2.26,
P= 0.189; HR 1.42 95% CI 0.84–2.38, P= 0.190, respectively, Table 2,
Figure 3). Adjusting for clinical characteristics only (HR = 1.72, 95%
CI 0.99–2.98, P= 0.055) or adjusting for clinical and pathological
features (HR = 1.56, 95% CI 0.90–2.70, P= 0.114), obesity remained
associated with CRPC, although the associations did not reach
significance (Table 2). Although overweight maintained a similar
HR for CRPC (1.34–1.36) on multivariable analyses, this was not
statistically significant (P⩾ 0.244). As a continuous variable, higher
BMI was not associated with higher risk of CRPC on both uni- and
multivariable analyses (all P⩾ 0.064).
DISCUSSION
Obesity is associated with aggressive PC at diagnosis.1,16,17
However, less is known about whether obesity has an impact on
long-term PC outcomes including outcomes after primary and
salvage treatments and ultimately PCSM among men diagnosed
with early stage disease and treated aggressively. Previously, we
found a BMI⩾ 35 kg/m2 was associated with BCR after RP.21 In a
separate study, we found obesity was associated with higher risk
of developing CRPC among a select group of men starting early
ADT as salvage treatment for BCR after RP.26 We hypothesized that
obesity is associated with more aggressive PC leading to worse
outcomes after both primary and salvage treatments, and that
obese men would be more likely to progress to CRPC and PCSM.
To test this hypothesis, we analyzed the risk of long-term PC-
specific outcomes in SEARCH. We found obese men had a
significantly increased risk of PCSM on both unadjusted and
multivariable analyses despite being more likely to receive post-
operative radiation and ADT. If validated in other studies, these
findings suggest higher BMI may be a modifiable risk factor for
PCSM despite aggressive treatment with RP.
A systematic review and meta-analysis found a 20% (95% CI − 1
to 46%) increased risk of PCSM after treatment per 5 kg/m2 increase
in BMI.2 Pooled estimates were calculated from six studies of mostly
Caucasian men that followed 18 203 PC patients after primary
treatment. However, only one of those six studies examined a pure
RP data set,19 while three studies examined PCSM after all types of
treatment,4,29,30 one examined an external beam radiation therapy
data set31 and one a brachytherapy data set.32 Nonetheless, for the
BMI category ⩾ 30 kg/m2, the relative risk for PCSM in the individual
studies was 41 in four studies (1.46–2.64) and o1 in one study
(0.9; one study did not report results by categorized BMI). Another
study published after the meta-analysis, which only included RP
patients found higher BMI was linked with increased risk of PCSM:
the HR was 1.51 for BMI 30–34.9 kg/m2 and 1.58 for BMI ⩾ 35 kg/
m2.20 Thus, the preponderance of the literature suggests higher BMI
is linked with greater PCSM after treatment with HRs between 1.5
and 2.5. However, few of the prior studies included a large
percentage of black men. As such the fact that our population was
all men from equal access VA Hospitals and included ~37% black is
noteworthy. Moreover, only one previous study33 performed
Figure 2. Cumulative incidence curve for biochemical recurrence
(BCR) by obesity groups.
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competing-risks analysis as was done in our present study. This is
very important in that obesity is a well-known risk factor for non-PC
death,34 including men treated with RP,20 due to competing causes
of mortality (that is, obese subjects do not live long enough to have
the opportunity to die from PC). Despite these key differences in
our study versus prior studies, our results were similar with the prior
literature (HR 1.97 for obesity in our unadjusted results) suggesting
an unequivocal link between obesity and PCSM.
In secondary analysis, on multivariable analysis each BMI unit was
associated with a significant, albeit modest, 1–2% increased risk
of BCR among 4263 racially diverse patients (~37% black men).
A systematic review and meta-analysis of 16 studies of mostly
Caucasian men, which followed 26 479 PC patients after primary
treatment, found a 21% (95% CI 11–31%) increased risk of BCR per
5 kg/m2 increase in BMI.2 As such, despite our results on the
association between obesity and PCSM being of similar magnitude
as in prior studies, the association between obesity and BCR was
slightly weaker than in prior studies. In our prior study from
SEARCH, the excess risk of BMI was largely limited to men with BMI
⩾35 kg/m2, a group we did not examine separately in this study
due to limited number of long-term events.21 In our prior study, the
multivariable risk of BMI as a continuous variable adjusted for
clinical features was 1.03 (95% CI 1.00–1.06), which is similar to the
1.01 (HR 1.00–1.02) in the current study. Therefore, our data are
consistent with our prior results and the preponderance of the data
that link higher BMI with BCR.
On adjusted analysis, despite obese men being equally likely to
receive ADT, there were no differences on CRPC risk by obesity
status, although the direction of the association suggested higher
risks in obese men, which did not reach statistical significance.
Only one prior study examined outcomes after ADT by BMI.26 In
that study, from SEARCH, we found a suggestion that higher BMI
was associated with higher risk for CRPC, although that study only
included men treated with early ADT. Herein, we extended our
findings to all surgically treated patients again finding a non-
significant suggestion that higher BMI is associated with CRPC.
Moreover, as the direction of the association (higher BMI equals
higher risk) is consistent with our findings that higher BMI was
associated with higher risks of BCR and PCSM and as it would be
unusual for a risk factor to be associated with BCR and PCSM but
not CRPC, this argues that the association with CRPC is likely real,
but underpowered. Nonetheless, given the non-significant nature
of the results larger studies with longer follow-up are needed to
confirm our findings.
One possible explanation for the worse outcomes among obese
men is that operating on obese men can be technically
challenging. Prior studies showed that obesity is associated with
capsular incision, reflecting a less-than ideal operation.35 However,
obesity remained associated with poor outcome even after
adjusting for pathological features including margin status,2,36
suggesting poor technique alone cannot explain the association
between obesity and aggressive PC. Potential mechanisms that
may link obesity with poor outcomes include higher serum insulin,
insulin-like growth factor-1, and leptin and lower adiponectin
Table 3. Hazard ratios for the associations between BMI and secondary treatment after radical prostatectomy
ADT XRT
N HR 95% CI P-value N HR 95% CI P-value
Unadjusted
BMI 667/4268 1.01 1.00–1.03 0.112 968/4268 1.03 1.01–1.04 o0.001
BMI category
Normal 144/955 1.00 Ref – 199/955 1.00 Ref –
Overweight 302/1941 1.04 0.84–1.28 0.722 432/1941 1.09 0.92–1.29 0.316
Obese 221/1372 1.12 0.90–1.39 0.331 337/1372 1.25 1.05-1.49 0.012
Multivariablea
BMI 667/4268 1.02 1.00–1.04 0.012 968/4252 1.02 1.01–1.04 o0.001
BMI category
Normal 144/955 1.00 Ref – 198/945 1.00 Ref –
Overweight 302/1941 1.12 0.91–1.38 0.273 432/1938 1.08 0.91–1.28 0.357
Obese 221/1372 1.26 1.01–1.58 0.044 338/1369 1.24 1.04–1.48 0.018
Multivariableb
BMI 667/4268 1.01 1.00–1.03 0.077 968/4252 1.02 1.01–1.03 0.004
BMI category
Normal 144/955 1.00 Ref – 198/945 1.00 Ref –
Overweight 302/1941 1.08 0.87–1.33 0.494 432/1938 1.05 0.89–1.24 0.566
Obese 221/1372 1.19 0.95–1.49 0.132 338/1369 1.15 0.97–1.38 0.117
Abbreviations: ADT, androgen-deprivation therapy; BMI, body mass index; CI, confidence interval; HR, hazard ratio; XRT, radiation therapy. aAdjusted for clinical
characteristics: age, PSA, biopsy Gleason score, surgical center and year of surgery. bAdjusted for clinical and pathological characteristics: age, PSA, year of
surgery, surgical center, pathological Gleason score, positive margins, extracapsular extension, seminal vesicles and lymph node involvement. The bold
numbers indicate that the associations are significant.
Figure 3. Cumulative incidence curve for castration-resistant pros-
tate cancer (CRPC) by obesity groups.
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levels in obese men.37 In addition, obese men tend to have lower
serum testosterone, which some studies have linked with an
increased risk of aggressive PC.38 Also, obesity is associated with
excess inflammation that may promote the development of more
aggressive tumors.4 Finally, in regards to outcomes after ADT,
there is a suggestion that traditional ADT, which is given in fixed
doses not adjusted for body surface area, results in less effective
testosterone suppression in obese men.39 Given data linking
better testosterone suppression with lower risks for CRPC and
PCSM,40 poor androgen suppression in obese men may contribute
to an already underlying more aggressive biology.
Our study was retrospective and only included men from the VA
system. Whether these results apply to the general population is
unknown. Height and weight were not obtained in a standardized
manner and are subject to human error in measurement.
However, errors in BMI measurement would tend to bias the
results toward the null, not create positive associations as
observed in our study. Testosterone levels were unavailable to
confirm castration after ADT. We only studied men who under-
went RP; whether these findings apply to men undergoing other
treatments is unknown. Although we did not adjust for other
treatments received between the time of BCR and PC death, we
found that obese men were in general either equally or more
likely to receive salvage treatments. Certainly there were no data
to suggest obese men were less likely to receive salvage
treatments. Thus, decreased receipt of these therapies cannot
explain the association between obesity and PCSM. Also, the
number of events was modest. As such, there are potential
concerns that our multivariable models may be overfitted. To
account for this, we focused on the crude analyses as our primary
outcome for these later outcomes of PCSM and CRPC. However,
the results of our multivariable models were nearly the same as
the unadjusted models, minimizing concerns that our adjusted
models were overfitted. Nonetheless, larger studies with longer
follow-up are needed to confirm our results. Finally, our results
support an association between obesity and PCSM. This does not
imply obesity causes more aggressive PC. Rather, obesity may be
associated with other factors such as poor diet or lack of exercise,
which we could not adjust for, which may explain this association.
More work is needed to understand the potential explanations for
the obesity-aggressive PC link.
In summary, our study supports the hypothesis that overweight
and obese men are at an increased risk of PCSM. Further studies
using larger populations with longer follow-up are necessary to
validate these findings, but if validated, these findings suggest
BMI may be a modifiable risk factor for PCSM after RP.
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